Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827277 | 1.00 | CYP3A4 (0.59) | CYP3A4ALDH1A1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29827751 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL217047 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1739571 | 0.83 | CYP3A4 (0.62) | CYP3A4ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL31545549 | 0.82 | CYP3A4 (0.61) | CYP3A4ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31493164 | 0.78 | CYP3A4 (0.59) | CYP3A4ALDH1A1SMN1; SMN2ALKBH5MEN1 | |
| SCHEMBL12000232 | 0.77 | CYP3A4 (0.77) | CYP3A4ALDH1A1CYP2D6SMN1; SMN2ALKBH5 | |
| SCHEMBL29633067 | 0.77 | CYP2D6 (0.55) | CYP2D6SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL5467647 | 0.77 | CYP2D6 (0.55) | CYP2D6SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL1465832 | 0.76 | CYP3A4 (0.69) | CYP3A4ALDH1A1SMN1; SMN2ALKBH5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | CYBIN IRL LIMITED (IE) | 2026-05-19 | — | — | US | disclosed |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-05-08 | — | — | US | disclosed |
| US-20240317704-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2024-09-26 | — | — | US | disclosed |
| WO-2023156453-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2023-08-24 | — | — | WO | disclosed |
| US-9522163-B2 | Methods of treating hepatitis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140141103-A1 | METHODS OF TREATING HEPATITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-22 | — | — | US | disclosed |
| US-20130202720-A1 | METHODS OF TREATING HEPATITIS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20120276220-A1 | Method of Treating Hepatitis | YALE UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
| EP-1505990-B1 | METHODS OF TREATING HEPATITIS | UNIV YALE (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1515753-A4 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | UNIV PITTSBURGH (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008156638-A2 | METHOD OF TREATING DISORDERS THAT WOULD BENEFIT FROM INCREASED LEVELS OF BILIRUBIN IN A SUBJECT | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080171021-A1 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008008513-A2 | COMBINATION TREATMENTS | BETH ISRAEL DEACONESS MEDICAL CENTER INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1515753-A1 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1505990-A2 | METHODS OF TREATING HEPATITIS | YALE UNIVERSITY (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040131703-A1 | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-08 | — | — | US | disclosed |
| US-20040052866-A1 | Methods of treating hepatitis | PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2004-03-18 | — | — | US | disclosed |
| WO-2004000368-A1 | PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF HEME DEGRADATION | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003096977-A2 | METHODS OF TREATING HEPATITIS | YALE UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317704-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | HTR2C, HTR2A, PNMT | CYP3A4 469/4885ALDH1A1 3746/4885CYP2D6 309/4885 |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | HTR2C, HTR1A, HTR2A | CYP3A4 570/4885ALDH1A1 2351/4885CYP2D6 113/4885 |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | PNMT, HTR7, HTR2C | CYP3A4 305/4885ALDH1A1 2656/4885CYP2D6 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.